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 P P+Cis P+Cb
Median age (range) (years) 63.0 (31, 85) 59.5 (26, 77) 61.0 (25, 80)
Male (%) 75.9 75.6 81.3
Karnofsky performance status ≥ 80, 
% of pts* 74.5 81.8 81.7
RR, % of pts (95% CI) 12.1 (9.1,15.7) 23.8 (17.3, 31.4) 16.8 (12.7, 21.7)
Disease control rate (responders 
+SD), % of pts, (95% CI) 58.1 (53.0, 63.0) 67.5 (59.5, 74.9) 66.3 (60.5, 71.8)
One-year survival rate, % (95% CI) 54.7 (42.6, 66.8) 67.9 (48.6, 85.5) 65.5 (54.6, 76.5)
Median TtPD (months) (95% CI) 4.9 (4.2, 5.8) 7.4 (5.6, 10.4) 6.9 (6.2, 7.4)
Leukopenia, Gr 3/4, % of pts 13.9 11.0 18.6
Neutropenia, Gr 3/4, % of pts 15.6 19.9 31.8
Thrombocytopenia, Gr 3/4, % of pts 4.9 12.9 18.6
Anemia, Gr 3/4, % of pts 9.2 10.4 12.4
*Approximately 95% of pts in each treatment arm contributed PS data.
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Exploring alternate methods to monitor therapy in Malignant 
Pleural Mesothelioma (MPM): comparing Radiological Response 
with Pulmonary Function Tests (PFTs) and Patient-reported 
Outcomes (PROs) using the LCSS-Meso Instrument. A study based 
on 410 patients from the EMPHACIS trial
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Background: Tumor growth in MPM presents technical challenges in 
measuring tumor volume or response radiographically even when using 
advanced imaging techniques. Additionally, MPM is highly symptom-
atic with nearly all patients presenting with three or more symptoms. 
Of major symptoms, dyspnea is rated by patients as having the greatest 
severity (Gralla ASCO 2003). Prior analyses indicated that improve-
ment in Forced Vital Capacity (FVC) correlated with improvements in 
patient-reported dyspnea (Gralla WCLC 2005) and that radiological 
response correlated with improvements in FVC (Paoletti ASCO 2003). 
This analysis was undertaken to determine whether dyspnea and other 
PROs of the 8-item LCSS-Meso and PFTs can enhance or replace 
radiological evaluation in monitoring response to therapy.
Methods: We analyzed data from 410 patients from the randomized 
MPM trial of cisplatin ± pemetrexed (Vogelzang JCO 2003). Changes 
from baseline in PROs and FVC were calculated at the time of response 
for patients with an investigator-determined radiological major re-
sponse (PR), at ﬁrst evidence of at least stable disease (SD) for patients 
with best response of SD, or at discontinuation for patients with best 
response of progressive disease (PD). PROs considered are reported in 
the table. Changes in PROs were summarized by radiological sub-
group which were further restricted to patients with or without an FVC 
improvement of at least 5%. Discriminant analyses were conducted to 
classify patients into two groups: PR+SD vs PD using changes in PROs 
and FVC as predictors. Prediction rates from the discriminant analyses 
were calculated as the number of correctly classiﬁed patients divided 
by total sample size. 
Results: PRs alone reported smaller PRO changes than those PRs 
with 5% improvement in FVC for dyspnea, pain, and symptom 
distress. Those with PD alone reported similar change to those with 
PD and&nbsp; < 5% improvement in FVC. The highest prediction 
rate (78.4%) was achieved by a combination discriminant of patient-
reported dyspnea and FVC; however, combining either two PROs 
(ie, dyspnea and activity level) or all PROs achieved nearly the same 
prediction rate (77% and 78%, respectively).
Mean Changes from Baseline and Prediction Rates
Item
PR (n=125) 
(A)
PR and >5% 
FVC (n=49) 
(A)
PD (n=120) 
(A)
PD and <5% 
FVC (n=50) 
(A)
Prediction 
Rate (%) (B)
Dyspnea 6.4 11.6 -18.8 -21.8 73.1
Fatigue 1.5 1.9 -22.0 -22.7 71.3
Pain 11.1 16.9 -12.3 -15.1 71.0
Symptom 
distress 5.8 9.2 -16.5 -16.2 67.3
Activity level 3.7 1.8 -22.6 -22.5 71.9
Global quality 
of life 4.6 1.9 -21.6 -20.4 72.5
All PROs - - - - 78.0
FVC - - - - 67.2
Dyspnea/FVC - - - - 78.4
Dyspnea/ 
Activity level - - - - 77.0
A. Visual Analogue Scale (0-100 mm) for each PRO item. Positive value indicates improvement.
B. Number of radiological PR+SD correctly classiﬁed by discriminant plus number of radiological PD 
correctly classiﬁed by discriminant divided by total sample size; sample sizes are approximately 410 for 
PROs and 296 for FVC.
Conclusions: Changes in patient-reported LCSS-Meso items correlate 
with radiological response to therapy. PROs appear to be at least as 
sensitive in predicting response to therapy as objective measures such 
as FVC. The LCSS-Meso may serve as an effective, inexpensive, and 
easy-to-administer alternative to radiological assessment for monitor-
ing response to therapy for MPM. Prospective studies are needed to 
conﬁrm these ﬁndings.
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Background: Selected patients with limited (cT1-3N0) malignant 
pleural mesothelioma are being considered for a multimodality therapy 
with induction chemotherapy followed by extrapleural resection and 
radiotherapy. Since invasion of the mediastinal lymph nodes is a nega-
tive prognostic factor, cervical mediastinoscopy is recommended for 
staging in these patients. Transoesophageal Endoscopic Ultrasound 
with a linear scanning ultrasound endoscope and real time guided ﬁne 
needle aspiration (EUS-FNA) enables mediastinal lymph node staging 
with high accuracy in lung cancer patients. 
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Hypothesis: EUS-FNA is useful to stage mediastinal lymph nodes in 
patients with malignant mesothelioma
Methods: A prospective two-center study investigated the diagnostic 
yield of EUS-FNA in the mediastinal lymph node staging of pleural 
mesothelioma as compared to surgical staging by cervical mediasti-
noscopy and post-resectional ﬁndings. Selected patients with pleural 
mesothelioma, were staged by spiral-CT, PET scanning, EUS-FNA and 
cervical mediastinoscopy. Patients without mediastinal lymph node 
invasion were treated with induction chemotherapy with 3 cycles of 
cisplatin and pemetrexed. In patients with a radiological respons or 
stable disease, an extrapleural pneumonectomy was performed with 
optional adjuvant radiotherapy. 
Results: Thirty-six patients were registered from June 2004 until Janu-
ary 2007. Data of 22 patients (61%) were available for this abstract. 
This involved 19 males (86%), the median age was 59 years (40-67 
years). Pathological subtypes were 1 sarcomatous, 18 epithelial and 
3 mixed mesotheliomas. EUS-FNA identiﬁed suspicious mediastinal 
lymph node in 9 patients (41%) and demonstrated malignant cells in 
3 (14%). Cervical mediastinoscopy was subsequently performed in 
17 (77%) patients. The results from the mediastinoscopy revealed no 
additional patients with malignant mediastinal lymph node invasion 
(EUS-FNA sensitivity 100%). 
Conclusion: This is the ﬁrst prospective study on the use of EUS-FNA 
in patients with malignant pleural mesothelioma. The prevalence of 
mediastinal lymph node metastasis in these selected mesothelioma 
patients is low. Although this is only a preliminary analysis, EUS-FNA 
appears to have an at least comparable yield as cervical mediastinosco-
py in identifying malignant mediastinal lymph nodes. The ﬁnal analysis 
will be presented at the conference.
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Background: Vascular endothelial growth factor (VEGF) plays a key 
role in mesothelioma biology. High serum VEGF is a negative prognos-
tic factor in mesothelioma patients which is inversely correlated with 
survival. Bevacizumab (Avastin™) is a recombinant humanized mono-
clonal antibody to VEGF. In phase II trials in mesothelioma patients, 
gemcitabine plus cisplatin on a 21-day schedule produces response 
rates of 16% to 26% and yields a median overall survival (OS) of 9.6 to 
13 months. We evaluated the role of adding bevacizumab to gem-
citabine plus cisplatin in a double-blind, placebo-controlled randomized 
phase II trial.
Methods: Eligible patients had unresectable, histologically-conﬁrmed 
mesothelioma; no prior chemotherapy; performance status 0-1; uni-
dimensionally measurable disease; no tumor invasion of major vessels; 
no bleeding or thrombosis. Progression-free survival (PFS) was the 
primary endpoint. Statistics: 90% power to detect a hazard ratio of 
0.57. Patients were stratiﬁed by performance status (0/1) and histology 
(epithelial/other). Gemcitabine 1250 mg/m2 days 1, 8, every 21 days, 
cisplatin 75 mg/m2 day 1 every 21 days, and bevacizumab 15 mg/kg or 
placebo day 1 every 21 days, was given for 6 cycles, then bevacizumab 
or placebo every 21 days until progression. Baseline plasma VEGF 
was measured. 115 patients enrolled from December 2001 to July 2005 
at 11 sites; 108 (GCB/GCP) 53/55 were evaluable. Male 74%/84%; 
median age 62/65 (range 44-78/20-84); performance status 1 55%/47%; 
epithelial 74%/67%, sarcomatoid/biphasic/other 26%/33%; pleural 
93%/91%, peritoneal 8%/7%, tunica vaginalis 0%/2%; thrombocytosis 
40%/40%, leukocytosis 53%/47%.
Results: Cycles administered (GCB/GCP): total 458/424, median 7/6, 
range 1-42/2-39. Median progression-free survival was 6.9/6.0 months 
(HR 0.93, p=0.88). Median overall survival was 15.6/14.7 months 
(p=0.91). 1-year survival was 59%/57%. Best response: complete 
0%/0%, partial 25%/22%, stable disease 51%/60%. Median VEGF 
(N=56) 131/154 pg/ml (range 31-1760/5-1786). Higher VEGF was 
associated with shorter progression-free (p=0.02) and overall survival 
(p=0.0066). Progression-free (p=0.043) and overall survival (p=0.028) 
were signiﬁcantly better for GCB than GCP in those patients with 
baseline VEGF levels at or below the median; in the high VEGF strata 
there were no signiﬁcant differences in PFS (p=0.24) or OS (p=0.90) 
between treatment arms. Toxicities that were statistically signiﬁcantly 
different between treatment arms (p <0.05), any grade, were: alopecia 
60%/38%; epistaxis 62%/24%; hypertension 45%/22%; non-neutrope-
nic infection 15%/4%; proteinuria 62%/47%; stomatitis 23%/7%. There 
were no statistically signiﬁcantly different toxicities grade 3 or greater. 
Conclusion: In mesothelioma patients, adding bevacizumab to gem-
citabine/cisplatin does not yield statistically signiﬁcant differences in 
progression-free survival, overall survival, response, or grade ı toxicity. 
Bevacizumab-treated patients with low VEGF levels had longer pro-
gression-free and overall survival. 
Supported by NCI grant N01-CM-17102.
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Background. A major obstacle to successful cancer treatment is the 
resistance of cancer cells to drugs. Tumors may develop drug resis-
tance during the course of treatment (acquired drug resistance) or 
may possess the innate drug resistance that plays a major role in poor 
prognosis. Mesothelioma is an aggressive, asbestos-related cancer 
that is locally invasive and rapidly (7-10 month) fatal. Until recently, 
mesotheliomas were considered to be notoriously chemoresistant 
tumors. Pemetrexed (Alimta®) plus cisplatin regimen changed this 
perception by demonstrating an increase in the response rate up to 45% 
and survival improvement in patients with unresectable mesotheliomas. 
However, along with the drug responsive patients, there was a cohort of 
patients with no positive outcome. Understanding the mechanisms of 
tumor innate drug sensitivity in mesothelioma is crucial for the devel-
opment of effective treatment regimens that may help to overcome both 
innate and acquired resistance.
Methods. We carried out a retrospective study on a cohort of mesothe-
lioma patients who showed or failed to show a strong primary response 
